NICE Clinical Guideline 90

Depression: the treatment and management of depression in adults

The recommendations from NICE cover:
  • Case identification and recognition
  • Low-intensity psychosocial interventions, including individual and group cognitive behavioral therapy
  • Drug treatment
  • Psychological interventions for relapse prevention
Web address: www.nice.org.uk/guidance/CG90
NICE Clinical Guideline 91

Depression in adults with a chronic physical health problem: treatment and management

The recommendations from NICE cover:
  • Identification and management in adults with a chronic physical health problem (such as cancer, heart disease, or a musculoskeletal, respiratory, or neurological disorder)
  • Low-intensity psychosocial interventions, including individual and group cognitive behavioural therapy
  • Antidepressant drugs
  • Collaborative care.
Web address: www.nice.org.uk/guidance/CG91
NICE Technology Appraisal 182

Prasugrel for the treatment of acute coronary syndromes with percutaneous coronary intervention

Summary:
  • Prasugrel in combination with aspirin is recommended as an option for people with acute coronary syndromes who are having percutaneous coronary intervention treatment only when:
    • immediate percutaneous coronary intervention is necessary to treat an ST-segment-elevation myocardial infarction or
    • a blood clot has blocked a stent during treatment with clopidogrel or
    • the patient has diabetes mellitus.
Web address: www.nice.org.uk/guidance/TA182
NICE Technology Appraisal 183

Topotecan for the treatment of recurrent and stage IVB cervical cancer

Summary:
  • Topotecan in combination with cisplatin is recommended as a possible treatment for women with recurrent or stage IVB cervical cancer only if they have not received cisplatin before
  • People who are currently being treated for recurrent and stage IVB cervical cancer with topotecan in combination with cisplatin (and whom have previously received cisplatin) should have the option to continue their therapy until they and their clinicians consider it appropriate to stop.
Web address: www.nice.org.uk/guidance/TA183